Published in Scand J Infect Dis on January 01, 1999
Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer (2013) 2.08
Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis (2004) 1.18
Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis (2007) 1.18
Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. BMC Infect Dis (2008) 0.93
Pre-emptive antibiotic treatment vs 'standard' treatment in patients with elevated serum procalcitonin levels after elective colorectal surgery: a prospective randomised pilot study. Langenbecks Arch Surg (2005) 0.89
Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever? PLoS One (2011) 0.85
Use of inflammatory molecules to predict the occurrence of fever in onco-hematological patients with neutropenia. Braz J Med Biol Res (2013) 0.82
Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. Support Care Cancer (2004) 0.81
A new prognostic model for chemotherapy-induced febrile neutropenia. Int J Clin Oncol (2015) 0.81
Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies. Support Care Cancer (2006) 0.79
Prediction of infectious complications by the combination of plasma procalcitonin level and localized infection before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2014) 0.78
Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6. Support Care Cancer (2015) 0.77
Role of Procalcitonin and Interleukin-6 in Predicting Cancer, and Its Progression Independent of Infection. PLoS One (2015) 0.76
Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer (2015) 0.76
Procalcitonin and C-reactive protein in differantiating to contamination from bacteremia. Braz J Microbiol (2015) 0.76
Serum procalcitonin is a marker for prediction of readmission from an intermediate care to an acute care hospital in neurosurgical patients. Surg Neurol Int (2015) 0.75
Canine pyometra: a model for the analysis of serum CXCL8 in inflammation. J Vet Med Sci (2015) 0.75
Intensive serial biomarker profiling for the prediction of neutropenic Fever in patients with hematologic malignancies undergoing chemotherapy: a pilot study. Hematol Rep (2014) 0.75
Role of Biomarkers as Predictors of Infection and Death in Neutropenic Febrile Patients after Hematopoietic Stem Cell Transplantation. Mediterr J Hematol Infect Dis (2015) 0.75
The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science (1999) 3.23
HTLV-III/LAV viral antigens in lymph nodes of homosexual men with persistent generalized lymphadenopathy and AIDS. Am J Pathol (1986) 2.77
Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob Agents Chemother (1998) 2.59
Imported Falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases. Clin Infect Dis (2002) 2.44
Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother (2000) 2.40
Prospective, randomised, double blind trial of prophylaxis with single dose of co-amoxiclav before percutaneous endoscopic gastrostomy. BMJ (1999) 2.28
Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet (2001) 2.06
Altered follicular dendritic cells and virus-like particles in AIDS and AIDS-related lymphadenopathy. Lancet (1985) 2.01
Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants Selected with a fluoroquinolone. Antimicrob Agents Chemother (2001) 1.93
Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for Helicobacter pylori. Gastroenterology (1994) 1.91
Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J (2004) 1.90
Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis (2005) 1.83
Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg (2000) 1.79
Trends in antibiotic use at a university hospital: defined or prescribed daily doses? Patient days or admissions as denominator? Infection (2006) 1.66
The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut (1997) 1.54
Spectrum of morphologic changes of lymph nodes from patients with AIDS or AIDS-related complexes. Prog Allergy (1986) 1.53
Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol (1994) 1.51
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother (1994) 1.49
gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli. J Antimicrob Chemother (1996) 1.48
Association of organic solvent tolerance and fluoroquinolone resistance in clinical isolates of Escherichia coli. J Antimicrob Chemother (1998) 1.47
Hypertension as a risk factor for cerebral injury during cardiopulmonary bypass. Protein S100B and transcranial Doppler findings. Anaesthesia (2001) 1.47
Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis (2000) 1.47
Musculoskeletal involvement in cystic echinococcosis: report of eight cases and review of the literature. AJR Am J Roentgenol (1997) 1.47
Reduction of unnecessary antibiotic therapy in newborn infants using interleukin-8 and C-reactive protein as markers of bacterial infections. Pediatrics (1999) 1.40
[Value of inpatient care in rheumatoid arthritis-an evidence based report]. Z Rheumatol (2004) 1.39
An epidemiologic survey of human alveolar echinococcosis in southwestern Germany. Römerstein Study Group. Am J Trop Med Hyg (1999) 1.36
T Cell Receptor Binding to a pMHCII Ligand Is Kinetically Distinct from and Independent of CD4. J Biol Chem (2000) 1.36
Comparison of procalcitonin with interleukin 8, C-reactive protein and differential white blood cell count for the early diagnosis of bacterial infections in newborn infants. Pediatr Infect Dis J (1999) 1.35
Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J Antimicrob Chemother (2000) 1.35
Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene (1999) 1.31
Inappropriate secretion of antidiuretic hormone and hyponatremia in severe falciparum malaria. Am J Trop Med Hyg (1994) 1.31
New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson. Arthritis Rheum (1998) 1.29
Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. Clin Infect Dis (2003) 1.29
Immunohistochemical, electron microscopic and in situ hybridization evidence for the involvement of lymphatics in the spread of HIV-1. AIDS (1988) 1.24
Inactivation of germline mutant APC alleles by attenuated somatic mutations: a molecular genetic mechanism for attenuated familial adenomatous polyposis. Am J Hum Genet (2000) 1.21
Alveolar liver echinococcosis: a comparative study of three imaging techniques. Infection (2001) 1.21
Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol (2000) 1.20
Synthesis, inactivation, and localization of extracellular and intracellular Escherichia coli hemolysins. J Bacteriol (1989) 1.19
Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother (2006) 1.16
Inhibition of HIV progression by dithiocarb. German DTC Study Group. Lancet (1990) 1.15
CD34+ hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus. Blood (1990) 1.15
Activation of the host response in human Plasmodium falciparum malaria: relation of parasitemia to tumor necrosis factor/cachectin, thrombin-antithrombin III, and protein C levels. Am J Med (1991) 1.13
Genomic rearrangements of the APC tumor-suppressor gene in familial adenomatous polyposis. Hum Genet (2000) 1.13
Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrob Agents Chemother (1996) 1.12
Identification of high-risk patients with aplastic anaemia in selection for allogeneic 0one-marrow transplantation. Lancet (1976) 1.10
Extrahepatic alveolar echinococcosis without liver involvement: a rare manifestation. Infection (2000) 1.10
Participants' perceptions of a phase I colon cancer chemoprevention trial. Control Clin Trials (1996) 1.09
Early biochemical characterization of soft-tissue trauma and fracture trauma. J Trauma (1999) 1.07
An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection (1998) 1.07
Ineffective erythropoiesis in acute human P. falciparum malaria. Blut (1983) 1.07
Subclass-specific serological reactivity and IgG4-specific antigen recognition in human echinococcosis. Trop Med Int Health (1997) 1.05
Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility toward the anus. J Acquir Immune Defic Syndr (2013) 1.04
Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis. Infection (1999) 1.04
Precipitable immune complexes in healthy homosexual men, acquired immune deficiency syndrome and the related lymphadenopathy syndrome. Clin Exp Immunol (1985) 1.04
Imbalance in the synthesis of collagen type I and collagen type III in smooth muscle cells derived from human varicose veins. J Vasc Res (2001) 1.03
Serological differentiation between cystic and alveolar echinococcosis by use of recombinant larval antigens. J Clin Microbiol (1993) 1.01
Development and validation of potential structure indicators for evaluating antimicrobial stewardship programmes in European hospitals. Eur J Clin Microbiol Infect Dis (2013) 1.00
Antibiotic use in Germany and European comparison. Dtsch Med Wochenschr (2004) 0.99
Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. Clin Infect Dis (1999) 0.98
Vascular origin of Kaposi's sarcoma. Expression of leukocyte adhesion molecule-1, thrombomodulin, and tissue factor. Am J Pathol (1994) 0.97
Systemic infection with Mycobacterium genavense following immunosuppressive therapy in a patient who was seronegative for human immunodeficiency virus. Clin Infect Dis (1997) 0.96
Interleukin-5 is the predominant cytokine produced by peripheral blood mononuclear cells in alveolar echinococcosis. Infect Immun (1995) 0.96
A prospective morphological study of facet joint integrity following intervertebral disc replacement with the CHARITE Artificial Disc. Eur Spine J (2005) 0.96
Comparison of defined versus recommended versus prescribed daily doses for measuring hospital antibiotic consumption. Infection (2009) 0.96
Neither heparin nor acetylsalicylic acid influence the clinical course in human Plasmodium falciparum malaria: a prospective randomized study. Am J Trop Med Hyg (1991) 0.96
HLA and alveolar echinococcosis. Tissue Antigens (1998) 0.95
Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect (2006) 0.95
Interleukin-8: a valuable tool to restrict antibiotic therapy in newborn infants. Acta Paediatr (2001) 0.94
Long-term follow-up of metabolic activity in human alveolar echinococcosis using FDG-PET. Nuklearmedizin (2008) 0.94
Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network. Eur J Clin Microbiol Infect Dis (2005) 0.93
Differential thymic selection outcomes stimulated by focal structural alteration in peptide/major histocompatibility complex ligands. Proc Natl Acad Sci U S A (1998) 0.93
Combination of vaccination and competitive exclusion to prevent Salmonella colonization in chickens: experimental studies. Int J Food Microbiol (1999) 0.93
Biosynthesis of skin collagens in normal and diabetic mice. Biochem J (1979) 0.93
[Hyperferritinemia in Still syndrome in the adult and reactive hemophagocytic syndrome]. Med Klin (Munich) (1997) 0.93
Autochthonous cystic echinococcosis in patients who grew up in Germany. Euro Surveill (2009) 0.92
IL-5 expressed by CD4+ lymphocytes from Echinococcus multilocularis-infected patients. Clin Exp Immunol (1997) 0.92
Echinococcus multilocularis metacestodes modulate cellular cytokine and chemokine release by peripheral blood mononuclear cells in alveolar echinococcosis patients. Clin Exp Immunol (2006) 0.92
Human echinococcosis: follow-up of 23 patients treated with mebendazole. Infection (1983) 0.92
A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine (2002) 0.92
Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis (2001) 0.92
Outcomes of invasive infection due to vancomycin-resistant Enterococcus faecium during a recent outbreak. Infection (2009) 0.91
Collagen synthesis and deposition in cultured fibroblasts from subcutaneous radiation-induced fibrosis. Modification as a function of cell aging. Matrix (1989) 0.91
A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis. Antimicrob Agents Chemother (1994) 0.91
Circulating tumor necrosis factor alpha (TNF), soluble TNF receptors, and interleukin-6 in human subacute bacterial endocarditis. Infect Immun (1993) 0.91
Leishmaniasis. Antibiot Chemother (1971) (1981) 0.90
Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother (1993) 0.90
5,6-carboxyfluorescein diacetate succinimidyl ester-labeled apoptotic and necrotic as well as detergent-treated cells can be traced in composite cell samples. Anal Biochem (2001) 0.90
Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis (2003) 0.89
Pro-inflammatory (IL-1beta, IL-18) cytokines and IL-8 chemokine release by PBMC in response to Echinococcus multilocularis metacestode vesicles. Parasite Immunol (2003) 0.89
Matrix therapy in regenerative medicine, a new approach to chronic wound healing. J Biomed Mater Res A (2009) 0.89
Antibiotic use in two cohorts of German intensive care units. J Hosp Infect (2006) 0.89
Supportive pentoxifylline in falciparum malaria: no effect on tumor necrosis factor alpha levels or clinical outcome: a prospective, randomized, placebo-controlled study. Am J Trop Med Hyg (1997) 0.89